La Major League Soccer elige a BioReference Laboratories de OPKO Health para proporcionar pruebas para detectar COVID-19 en empleados y jugadores

BioReference initiates COVID-19 testing for all Major League Soccer players, match officials, and Club and League employees participating in the MLS is Back Tournament

MLS will support COVID-19 antibody testing for the Orlando community utilizing BioReference’s community collection program

ELMWOOD PARK, N.J., 9 de julio de 2020 – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), will conduct COVID-19 testing for all Major League Soccer (MLS) players as well as match officials, and Club and League staff participating in the MLS is Back Tournament. MLS has chosen BioReference as its laboratory to assist in informing its return-to-play policies for the Tournament kicking off in Orlando in early July.

In addition to providing testing to players, match officials, and staff, MLS is working with BioReference to provide COVID-19 antibody testing to the Orlando community. MLS is supporting the latest community collection location at the Orlando Vineland Premium Outlets, which began on July 6. The collection location is open Mondays through Saturdays from 8:00 AM to 6:00 PM ET.   

“We are honored to be providing testing solutions to Major League Soccer as it prepares to restart its season,” said Jon R. Cohen, M.D., Executive Chairman of BioReference Laboratories. “The leadership of MLS worked diligently with us to develop a COVID-19 PCR and antibody testing strategy with the goal of providing the safest possible environment for the players, coaches and staff to begin to play again.”

Para obtener más información, visite https://www.bioreference.com/coronavirus/employers-and-government-authorities/.    

Información acerca de BioReference Laboratories, Inc.

BioReference provides comprehensive testing to physicians, clinics, hospitals, employers, government units, correctional institutions and medical groups.  BioReference has been working expeditiously to develop and offer test services that will yield high quality and accurate results, including a molecular test for helping with COVID-19 diagnosis and a serology test to help indicate possible COVID-19 exposure. The company is in network with the five largest health plans in the United States, operates a network of 11 laboratory locations, and is backed by a medical staff of more than 120 M.D., Ph.D. and other professional level clinicians and scientists.  With a leading position in the areas of genetics, women’s health, maternal fetal medicine, oncology and urology, BioReference and its specialty laboratories, GenPath and GeneDx, are advancing the course of modern medicine.  For more information, visit www.bioreference.com.

Información acerca de OPKO Health, Inc.

OPKO es una compañía biofarmacéutica y de diagnóstico multinacional que busca posicionarse como líder de la industria en grandes mercados de rápido crecimiento, a través de sus tecnologías exclusivas y su experiencia e innovación en el descubrimiento, el desarrollo y la comercialización. Para obtener más información, visite www.opko.com.

Advertencia respecto de declaraciones con perspectivas de futuro

This press release contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” and other words of similar meaning, including statements regarding BioReference’s antibody screening test, the availability of the test and the role and value of the information provided and its impact on decisions relative to the safety of employees and customers, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Muchos factores podrían hacer que nuestras actividades o resultados reales difieran sustancialmente de las actividades y resultados anticipados en las declaraciones con perspectivas de futuro. Estos factores incluyen aquellos descritos en los informes anuales de OPKO Health, Inc. los informes anuales del formulario 10-K de OPKO Health, Inc. presentados y a presentarse ante la Comisión de Bolsa y Valores y en otras presentaciones nuestras ante la Comisión de Bolsa y Valores. Además, las declaraciones con perspectivas de futuro también pueden verse afectadas de manera adversa por factores generales del mercado, desarrollo de productos de la competencia, disponibilidad de productos, normas y leyes federales y estatales, el proceso regulatorio de nuevos productos e indicaciones, problemas de fabricación que puedan surgir, posiciones de patentes y litigios, entre otros factores. Las proyecciones que contiene este comunicado de prensa solo expresan la situación a la fecha en que se realizaron, y no asumimos obligación alguna de actualizar las proyecciones. Tenemos la intención de que todas las declaraciones con perspectivas de futuro estén sujetas a las disposiciones de puerto seguro de la ley PSLRA.

Contacto de BioReference Laboratories para los medios:

Hillary Titus, htitus@bioreference.com

Powered by Translations.com GlobalLink OneLink Software